Principal Financial Group Inc. Sells 26,798 Shares of SOPHiA GENETICS SA (NASDAQ:SOPH)

Principal Financial Group Inc. lessened its stake in SOPHiA GENETICS SA (NASDAQ:SOPH) by 1.8% during the fourth quarter, HoldingsChannel reports. The institutional investor owned 1,428,344 shares of the company’s stock after selling 26,798 shares during the period. Principal Financial Group Inc.’s holdings in SOPHiA GENETICS were worth $4,456,000 at the end of the most recent quarter.

Separately, Green Alpha Advisors LLC boosted its holdings in SOPHiA GENETICS by 119.3% in the fourth quarter. Green Alpha Advisors LLC now owns 47,216 shares of the company’s stock valued at $145,000 after acquiring an additional 25,686 shares during the last quarter. Institutional investors own 31.59% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Craig Hallum started coverage on shares of SOPHiA GENETICS in a report on Wednesday, December 18th. They set a “buy” rating and a $11.00 price target for the company. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat.com, SOPHiA GENETICS has an average rating of “Moderate Buy” and a consensus target price of $7.40.

SOPHiA GENETICS Stock Performance

SOPH stock opened at $3.57 on Tuesday. The firm has a market cap of $233.39 million, a PE ratio of -3.28 and a beta of 1.03. The company has a current ratio of 3.80, a quick ratio of 3.59 and a debt-to-equity ratio of 0.12. The stock has a 50-day moving average price of $3.58 and a 200-day moving average price of $3.56. SOPHiA GENETICS SA has a 1-year low of $2.70 and a 1-year high of $7.37.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific.